HemminkiK, EngC. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet2004;41:801–807.
HemminkiKEngC. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004;41:801–807.
)| false
AhsanH, NeugutAI, GarbowskiGC et al.. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900–905.
AhsanHNeugutAIGarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998;128:900–905.
)| false
BonelliL, MartinesH, ConioM et al.. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513–517.
BonelliLMartinesHConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988;41:513–517.
)| false
O’ConnellJB, MaggardMA, KoCY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst2004;96:1420–1425.
O’ConnellJBMaggardMAKoCY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420–1425.
)| false
ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:1016–1025.
ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000;124:1016–1025.
)| false
ComptonCC, FieldingLP, BurgartLJ et al.. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med2000;124:979–994.
ComptonCCFieldingLPBurgartLJ. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979–994.
)| false
GreeneFL, StewartAK, NortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg2002;236:416–421.
GreeneFLStewartAKNortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416–421.
)| false
Le VoyerT, SigurdsonE, HamlinA et al.. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol2003;21:2912–2919.
Le VoyerTSigurdsonEHamlinA. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912–2919.
)| false
NewlandRC, DentOF, LyttleMN et al.. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer1994;73:2076–2082.
NewlandRCDentOFLyttleMN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994;73:2076–2082.
)| false
ChapuisPH, DentOF, BokeyEL et al.. Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg2004;91:349–354.
ChapuisPHDentOFBokeyEL. Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg 2004;91:349–354.
)| false
RedstonM, ComptonCC, MiedemaBW et al.. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B trial 80001. J Clin Oncol2006;24:878–883.
RedstonMComptonCCMiedemaBW. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B trial 80001. J Clin Oncol 2006;24:878–883.
)| false
BertagnolliM, MiedemaB, RedstonM et al.. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg2004;240:624–628; discussion 628–630.
BertagnolliMMiedemaBRedstonM. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 2004;240:624–628; discussion 628–630.
)| false
NouraS, YamamotoH, MiyakeY et al.. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759–767.
NouraSYamamotoHMiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res 2002;8:759–767.
)| false
AmadoRG, WolfM, PeetersM et al.. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–1634.
)| false
Khambata-FordS, GarrettCR, MeropolNJ et al.. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230–3237.
)| false
De RoockW, PiessevauxH, De SchutterJ et al.. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508–515.
)| false
PuntCJ, TolJ, RodenburgCJ et al.. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4011.
PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract LBA 4011.
)| false
BokemeyerC, BondarenkoI, MakhsonA et al.. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–771.
BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663–771.
)| false
TejparS, PeetersM, HumbletY et al.. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4001.
TejparSPeetersMHumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4001.
)| false
Van CutsemE, Henning-KohneC, HitreE et al.. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 36014:1408–1417.
Van CutsemEHenning-KohneCHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 36014:1408–1417.
)| false
LièvreA, BachetJB, BoigeV et al.. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
LièvreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–379.
)| false
KarapetisCS, Khambata-FordS, JonkerDJ et al.. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:1757–1765.
LievreA, BachetJ-B, BoigeV et al.. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol2008;26:374–379.
LievreABachetJ-BBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol 2008;26:374–379.
)| false
ArtaleS, Sartore-BianchiA, VeroneseSM et al.. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
ArtaleSSartore-BianchiAVeroneseSM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217–4219.
)| false
Etienne-GrimaldiMC, FormentoJL, FrancoualM et al.. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res2008;14:4830–4835.
Etienne-GrimaldiMCFormentoJLFrancoualM. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res 2008;14:4830–4835.
)| false
NivatvongsS, RojanasakulA, ReimanHM et al.. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum1991;34:323–328.
NivatvongsSRojanasakulAReimanHM. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum 1991;34:323–328.
)| false
VolkEE, GoldblumJR, PetrasRE et al.. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology1995;109:1801–1807.
VolkEEGoldblumJRPetrasRE. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995;109:1801–1807.
)| false
SeitzU, BohnackerS, SeewaldS et al.. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum2004;47:1789–1796.
SeitzUBohnackerSSeewaldS. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004;47:1789–1796.
)| false
HaggittRC, GlotzbachRE, SofferEE, WrubleLD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology1985;89:328–336.
HaggittRCGlotzbachRESofferEEWrubleLD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985;89:328–336.
)| false
CrawleyJ, PetrasR, CareyW et al.. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive cancer?Gastroenterology1986;91:419–427.
BalthazarEJMegibowAJHulnickDNaidichDP. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol 1988;150:301–306.
)| false
JosephNE, SigurdsonER, HanlonAL et al.. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol2003;10:213–218.
JosephNESigurdsonERHanlonAL. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003;10:213–218.
)| false
BergerAC, SigurdsonER, LeVoyerT et al.. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol2005;23:8706–8712.
BergerACSigurdsonERLeVoyerT. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706–8712.
)| false
LacyAM, Garcia-ValdecasasJC, DelgadoS et al.. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet2002;359:2224–2229.
LacyAMGarcia-ValdecasasJCDelgadoS. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002;359:2224–2229.
)| false
BuunenM, VeldkampR, HopWC et al.. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol2009;10:44–52.
BuunenMVeldkampRHopWC. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 2009;10:44–52.
)| false
JayneDG, Guillou, ThorpeH et al.. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol2007;25:3061–3068.
JayneDGGuillouThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol 2007;25:3061–3068.
)| false
Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med2004;350:2050–2059.
Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004;350:2050–2059.
)| false
FleshmanJ, SargentDJ, GreenE et al.. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST study group trial. Ann Surg2007;246:655–664.
FleshmanJSargentDJGreenE. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST study group trial. Ann Surg 2007;246:655–664.
)| false
JacksonTD, KaplanGG, ArenaG et al.. Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg2007;204:439–446.
JacksonTDKaplanGGArenaG. Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg 2007;204:439–446.
)| false
KuhryE, BonjerHJ, HaglindE et al.. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc2005;19:687–692.
KuhryEBonjerHJHaglindE. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc 2005;19:687–692.
)| false
NelsonH, WeeksJC, WieandHS. Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr1995;19:51–56.
NelsonHWeeksJCWieandHS. Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr 1995;19:51–56.
)| false
AndreT, BoniC, Mounedji-BoudiafL et al.. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med2004;350:2343–2351.
AndreTBoniCMounedji-BoudiafL. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351.
)| false
de GramontA, BoniC, NavarroM et al.. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3501.
de GramontABoniCNavarroM. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3501.
)| false
de GramontA, BoniC, NavarroM et al.. Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4007.
de GramontABoniCNavarroM. Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4007.
)| false
SargentDJ, WieandHS, HallerDG et al.. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2005;23:8664–8670.
SargentDJWieandHSHallerDG. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664–8670.
)| false
SargentDJ. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient ACCENT dataset [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.
SargentDJ. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient ACCENT dataset [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4008.
)| false
SargentD, SobreroA, GrotheyA et al.. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2009;27:872–877.
SargentDSobreroAGrotheyA. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872–877.
)| false
AndreT, BoniC, NavarroM et al.. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009;27:3109–3116.
AndreTBoniCNavarroM. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–3116.
)| false
SaltzL, NiedzwieckiD, HollisD et al.. Irinotecan fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol2007;25:3456–3461.
SaltzLNiedzwieckiDHollisD. Irinotecan fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456–3461.
)| false
RothenbergML, MeropolNJ, PoplinEA et al.. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol2001;19:3801–3807.
RothenbergMLMeropolNJPoplinEA. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801–3807.
)| false
Van CutsemE, LabiancaR, BodokyG et al.. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol2009;27:3117–3125.
Van CutsemELabiancaRBodokyG. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117–3125.
)| false
YchouM, RaoulJL, DouillardJY et al.. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol2009;20:674–680.
YchouMRaoulJLDouillardJY. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009;20:674–680.
)| false
WolmarkN, WieandH, KueblerJ et al.. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3500.
WolmarkNWieandHKueblerJ. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3500.
)| false
KueblerJP, WieandS, O’ConnellMJ et al.. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol2007;25:2198–2204.
KueblerJPWieandSO’ConnellMJ. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198–2204.
)| false
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet1995;345:939–944.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939–944.
)| false
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol1999;17:1356–1363.
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356–1363.
)| false
GillS, LoprinziCL, SargentDJ et al.. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2004;22:1797–1806.
GillSLoprinziCLSargentDJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol 2004;22:1797–1806.
)| false
WolmarkN, RocketteH, MamounasE et al.. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol1999;17:3553–3559.
WolmarkNRocketteHMamounasE. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553–3559.
)| false
HallerDG, CatalanoPJ, MacdonaldJS et al.. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol2005;23:8671–8678.
HallerDGCatalanoPJMacdonaldJS. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005;23:8671–8678.
)| false
Quasar Collaborative GroupGrayR, BarnwellJ, McConkeyC et al.. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet2007;370:2020–2029.
Quasar Collaborative GroupGrayRBarnwellJMcConkeyC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020–2029.
)| false
BensonABIII, SchragD, SomerfieldMR et al.. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol2004;22:3408–3419.
BensonABIIISchragDSomerfieldMR. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408–3419.
)| false
LoveN, BylundC, MeropolNJ et al.. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4200.
LoveNBylundCMeropolNJ. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4200.
)| false
BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal appro0aches in early-stage disease. Clin Cancer Res2007;13:6913s–6920s.
BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal appro0aches in early-stage disease. Clin Cancer Res 2007;13:6913s–6920s.
)| false
Van CutsemE, NordlingerB, AdamR et al.. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:2212–2221.
Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212–2221.
)| false
YooPS, Lopez-SolerRI, LongoWE, ChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202–207.
YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6:202–207.
)| false
AlbertsSR, HorvathWL, SternfeldWC et al.. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:9243–9249.
AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243–9249.
)| false
TsaiM, SuY, HoM et al.. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol2007;14:786–794.
TsaiMSuYHoM. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol 2007;14:786–794.
)| false
PoultsidesGA, ServaisEL, SaltzLB et al.. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:3379–3384.
PoultsidesGAServaisELSaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:3379–3384.
)| false
StanglRAltendorf-HofmannACharnleyRMScheeleJ.. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405–1410.
)| false
ChotiMA, SitzmannJV, TiburiMF et al.. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759–766.
ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–766.
)| false
PawlikTM, ScogginsCR, ZorziD et al.. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715–722.
PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715–722.
)| false
CharnsangavejC, ClaryB, FongY et al.. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1261–1268.
CharnsangavejCClaryBFongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1261–1268.
)| false
PozzoC, BassoM, CassanoA et al.. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933–939.
PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–939.
)| false
Altendorf-HofmannA, ScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165–192.
Altendorf-HofmannAScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 2003;12:165–192.
)| false
FolprechtG, GrotheyA, AlbertsS et al.. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:1311–1319.
FolprechtGGrotheyAAlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311–1319.
)| false
ReddySK, PawlikTM, ZorziD et al.. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol2007;14:3481–3491.
ReddySKPawlikTMZorziD. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007;14:3481–3491.
)| false
CoveyAM, BrownKT, JarnaginWR et al.. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg2008;247:451–455.
CoveyAMBrownKTJarnaginWR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008;247:451–455.
)| false
AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737–739.
AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg 2009;197:737–739.
)| false
AbdallaEK, VautheyJN, EllisLM et al.. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818–825.
AbdallaEKVautheyJNEllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–825.
)| false
HurH, KoYT, MinBS et al.. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728–736.
HurHKoYTMinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197:728–736.
)| false
BilchikAJ, PostonG, AdamR, ChotiMA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol2008;26:5320–5321.
BilchikAJPostonGAdamRChotiMA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol 2008;26:5320–5321.
)| false
LeonardGD, BrennerB, KemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:2038–2048.
BenoistS, BrouquetA, PennaC et al.. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:3939–3945.
BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol 2006;24:3939–3945.
)| false
AdamR, AvisarE, AricheA et al.. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol2001;8:347–353.
AdamRAvisarEAricheA. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol 2001;8:347–353.
)| false
RivoireM, De CianF, MeeusP et al.. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:2283–2292.
RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:2283–2292.
)| false
VautheyJN, PawlikTM, RiberoD et al.. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:2065–2072.
VautheyJNPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065–2072.
)| false
PawlikTM, PoonRT, AbdallaEK et al.. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450–457; discussion 457–458.
PawlikTMPoonRTAbdallaEK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450–457; discussion 457–458.
)| false
EliasD, LiberaleG, VernereyD et al.. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900–909.
EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900–909.
)| false
AdamR, DelvartV, PascalG et al.. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644–657.
AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–657.
)| false
DelaunoitT, AlbertsSR, SargentDJ et al.. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol2005;16:425–429.
NordlingerB, SorbyeH, GlimeliusB et al.. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet2008;37:1007–1016.
NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 2008;37:1007–1016.
)| false
TanBR, ZubalB, Hawkinsw et al.. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. Gastrointestinal Cancers Symposium2009; Abstract 497.
FolprechtG, GruenbergerT, HartmannJT et al.. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 296.
FolprechtGGruenbergerTHartmannJT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 296.
)| false
SouglakosJ, AndroulakisN, SyrigosK et al.. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer2006;94:798–805.
SouglakosJAndroulakisNSyrigosK. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer 2006;94:798–805.
)| false
FalconeA, RicciS, BrunettiI et al.. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–1676.
)| false
ScappaticciFA, FehrenbacherL, CartwrightT et al.. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol2005;91:173–180.
GruenbergerB, TamandlD, SchuellerJ et al.. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:1830–1835.
ReddySK, MorseMA, HurwitzHI et al.. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–106.
ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:96–106.
)| false
Rubbia-BrandtL, AudardV, SartorettiP et al.. Severe hepatic sinusoidal obstructjion associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;15:460–466.
Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinusoidal obstructjion associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–466.
)| false
ZorziD, KishiY, MaruDM et al.. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 295.
ZorziDKishiYMaruDM. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 295.
)| false
LeeWS, YunSH, ChunHK et al.. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699–704.
LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007;22:699–704.
)| false
HeadrickJR, MillerDL, NagorneyDM et al.. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg2001;71:975–979; discussion 979–980.
HeadrickJRMillerDLNagorneyDM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–979; discussion 979–980.
)| false
MitryE, FieldsALA, BleibergH et al.. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol2008;26:4906–4911.
MitryEFieldsALABleibergH. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906–4911.
)| false
KemenyN, HuangY, CohenAM et al.. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:2039–2048.
KemenyNHuangYCohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039–2048.
)| false
MulcahyMF, LewandowskiRJ, IbrahimSM et al.. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer2009;115:1849–1858.
KatzAW, Carey-SampsonM, MuhsAG et al.. Hypofractionated stereotactic body radiation therapy (SBRT) for patients with limited hepatic metastases. Int J Radiat Oncol Biol Phys2007;67:793–798.
BartlettDL, BerlinJ, LauwersGY et al.. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1284–1292.
YanTD, BlackD, SavadyR, SugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol2006;24:4011–4019.
YanTDBlackDSavadyRSugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011–4019.
)| false
EsquivelJ, SticcaR, SugarbakerP et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol2007;14:128–133.
EsquivelJSticcaRSugarbakerP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128–133.
)| false
PelosiE, DeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol2007;33:1–6.
PelosiEDeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 2007;33:1–6.
)| false
GoldbergRM, RothenbergML, Van CutsemE et al.. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:38–50.
GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38–50.
)| false
GoldbergRM, SargentDJ, MortonRF et al.. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol2006;24:3347–3353.
GoldbergRMSargentDJMortonRF. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347–3353.
)| false
DouillardJY, CunninghamD, RothAD et al.. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:1041–1047.
DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.
)| false
FuchsCS, MooreMR, HarkerG et al.. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807–814.
FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807–814.
)| false
PetrelliN, HerreraL, RustumY et al.. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:1559–1565.
PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559–1565.
)| false
Van CutsemE, TwelvesC, CassidyJ et al.. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:4097–4106.
Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–4106.
)| false
Van CutsemE, HoffPM, HarperP et al.. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:1190–1197.
Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190–1197.
)| false
BurokerTR, O’ConnellMJ, WieandHS et al.. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:14–20.
BurokerTRO’ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14–20.
)| false
de GramontA, BossetJF, MilanC et al.. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808–815.
de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–815.
)| false
Maindrault-GoebelF, LouvetC, AndreT et al.. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:1338–1342.
Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338–1342.
)| false
Van CutsemE, PeetersM, SienaS et al.. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:1658–1664.
Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–1664.
)| false
CunninghamD, HumbletY, SienaS et al.. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337–345.
CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.
)| false
LentzF, TranA, ReyE et al.. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:21–33.
LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics 2005;5:21–33.
)| false
GoldbergRM, SargentDJ, MortonRF et al.. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:23–30.
GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.
)| false
TournigandC, AndreT, AchilleE et al.. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229–237.
TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.
)| false
DelaunoitT, GoldbergRM, SargentDJ et al.. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer2004;101:2170–2176.
DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004;101:2170–2176.
)| false
CheesemanSL, JoelSP, ChesterJD et al.. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393–399.
CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393–399.
)| false
de GramontA, FigerA, SeymourM et al.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:2938–2947.
de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.
)| false
ColucciG, GebbiaV, PaolettiG et al.. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol2005;23:4866–4875.
ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23:4866–4875.
)| false
CassidyJ, ClarkeS, Diaz-RubioD et al.. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 270.
CassidyJClarkeSDiaz-RubioD. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 270.
)| false
CassidyJ, TaberneroJ, TwelvesC et al.. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:2084–2091.
CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084–2091.
)| false
PorschenR, ArkenauHT, KubickaS et al.. Phase III study of capecitabine plus oxaliplatin compared with fluororuracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:4217–4223.
PorschenRArkenauHTKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluororuracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217–4223.
)| false
JagerE, HeikeM, BernhardH et al.. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:2274–2279.
JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:2274–2279.
)| false
WolmarkN, RocketteH, FisherB et al.. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:1879–1887.
WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879–1887.
)| false
SaltzLB, ClarkeS, Díaz-RubioE et al.. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:2013–2039.
SaltzLBClarkeSDíaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–2039.
)| false
SaltzLB, ClarkeS, Diaz-RubioE et al.. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 238.
SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 238.
)| false
KabbinavarFF, SchulzJ, McCleodM et al.. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:3697–3705.
KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697–3705.
)| false
HurwitzHI, FehrenbacherL, HainsworthJD et al.. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:3502–3508.
HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502–3508.
)| false
HochsterHS, HartLL, RamanathanRK et al.. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523–3529. Erratum in: J Clin Oncol2008;26:4697.
HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523–3529. Erratum in: J Clin Oncol 2008;26:4697.
)| false
KabbinavarFF, HambletonJ, MassRD et al.. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:3706–3712.
KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706–3712.
)| false
HurwitzH, FehrenbacherL, NovotnyW et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:2335–2342.
HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
)| false
FuchsCS, MarshallJ, MitchellEP et al.. Updated results of BICC-C study comparing first-line irinotecan /fluoropyrimidine combinations +/- celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 276.
FuchsCSMarshallJMitchellEP. Updated results of BICC-C study comparing first-line irinotecan /fluoropyrimidine combinations +/- celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 276.
)| false
FuchsCJ, MarshallJ, BarruecoJ. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol2007;24:4779–4786.
FuchsCJMarshallJBarruecoJ. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007;24:4779–4786.
)| false
SoberoA, AcklandS, CarrionR et al.. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 3544.
SoberoAAcklandSCarrionR. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 3544.
)| false
GiantonioB, CatalanoP, MeropolN et al.. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol2007;25:1539–1544.
GiantonioBCatalanoPMeropolN. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25:1539–1544.
)| false
CannistraSA, MatulonisUA, PensonRT et al.. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5150–5152.
CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5150–5152.
)| false
InnocentiF, UndeviaSD, IyerL et al.. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol2004;22:1382–1388.
InnocentiFUndeviaSDIyerL. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382–1388.
)| false
LabCorp Capsule. UGT1A1 irinotecan toxicity. Managing medication dosing and predicting response to treatment of cancer with irinotecan (Camptosar, CPT-11). 2006. Available at www.lapcorp.com.
LabCorp Capsule. UGT1A1 irinotecan toxicity. Managing medication dosing and predicting response to treatment of cancer with irinotecan (Camptosar, CPT-11). 2006. Available at www.lapcorp.com.
)| false
TournigandC, CervantesA, FigerA et al.. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol2006;24:394–400.
TournigandCCervantesAFigerA. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 2006;24:394–400.
)| false
Maindrault-GoebelF, LledoG, GhibaudelB et al.. Final results for OPTIMOX-2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4013.
Maindrault-GoebelFLledoGGhibaudelB. Final results for OPTIMOX-2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4013.
)| false
GrotheyA, SargentD, GoldbergRM, SchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004;22:1209–1214.
GrotheyASargentDGoldbergRMSchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–1214.
)| false
CunninghamD, PyrhonenS, JamesRD et al.. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:1413–1418.
CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.
)| false
RougierP, Van CutsemE, BajettaE et al.. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:1407–1412.
RougierPVan CutsemEBajettaE. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–1412.
)| false
PitotH, RowlandK, SargentDJ et al.. N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3506.
PitotHRowlandKSargentDJ. N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3506.
)| false
SaltzLB, MeropolNJ, LoehrerPJSr et al.. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol2004;22:1201–1208.
SaltzLBMeropolNJLoehrerPJSr. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201–1208.
)| false
SaltzL, RubinM, HochsterH et al.. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol2001;20:Abstract 7.
SaltzLRubinMHochsterH. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol 2001;20:Abstract 7.
)| false
SobreroAF, MaurelJ, FehrenbacherL et al.. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008;26:2311–2319.
SobreroAFMaurelJFehrenbacherL. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311–2319.
)| false
HechtJR, MitchellE, ChidiacT et al.. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672–680.
HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672–680.
)| false
HelblingD, BornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol2007;18:963–964.
HelblingDBornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007;18:963–964.
)| false
HeunJ, HolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer2007;6:529–531.
HeunJHolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007;6:529–531.
)| false
BerlinJ, van CutsemE, PeetersM et al.. Predictive value of skin toxicity severity for response to panitumumab in pateints with metastatic colorectal cancer: a pooled analysis of five clinical trials [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4134.
BerlinJvan CutsemEPeetersM. Predictive value of skin toxicity severity for response to panitumumab in pateints with metastatic colorectal cancer: a pooled analysis of five clinical trials [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4134.
)| false
HechtJR, MitchellE, ChidiacT et al.. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672–680.
HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672–680.
)| false
GoldbergRM, KohneGH, SeymourMT et al.. A pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials of 6,286 patients with metastatic colorectal cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4011.
GoldbergRMKohneGHSeymourMT. A pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials of 6,286 patients with metastatic colorectal cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4011.
)| false
HoffPM, PazdurR, LassereY et al.. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol2004;22:2078–2083.
HoffPMPazdurRLassereY. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22:2078–2083.
)| false
PietraN, SarliL, CostiR et al.. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum1998;41:1127–1133.
PietraNSarliLCostiR. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127–1133.
)| false
SeccoGB, FardelliR, GianquintoD et al.. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol2002;28:418–423.
SeccoGBFardelliRGianquintoD. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002;28:418–423.
)| false
Rodriguez-MorantaF, SaloJ, ArcusaA et al.. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol2006;24:386–393.
Rodriguez-MorantaFSaloJArcusaA. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006;24:386–393.
)| false
FigueredoA, CharetteML, MarounJ et al.. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol2004;22:3395–3407.
FigueredoACharetteMLMarounJ. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395–3407.
)| false
RenehanAG, EggerM, SaundersMP, O’DwyerST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ2002;324:813.
RenehanAGEggerMSaundersMPO’DwyerST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813.
)| false
DeschCE, BensonABIII, SomerfieldMR et al.. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2005;23:8512–8519.
DeschCEBensonABIIISomerfieldMR. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512–8519.
)| false
PfisterDGBensonABIIISomerfieldMR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004;350:2375–2382.
)| false
LockerGY, HamiltonS, HarrisJ et al.. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol2006;24:5313–5327.
LockerGYHamiltonSHarrisJ. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–5327.
)| false
RexDK, KahiCJ, LevinB et al.. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin2006;56:160–167.
RexDKKahiCJLevinB. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006;56:160–167.
)| false
GreenRJ, MetlayJP, PropertK et al.. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med2002;136:261–269.
GreenRJMetlayJPPropertK. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002;136:261–269.
)| false
DignamJL, PoliteBN, YothersG et al.. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:1647–1654.
DignamJLPoliteBNYothersG. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:1647–1654.
)| false
MeyerhardtJA, HeseltineD, NiedzwieckiD et al.. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol2006;24:3535–3541.
MeyerhardtJAHeseltineDNiedzwieckiD. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006;24:3535–3541.
)| false